This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Woonsocket, RI, CVS Health Corporation (formerly known as CVS Caremark Corporation) is a pharmacy innovation company with integrated offerings across the entire spectrum of pharmacy care. On Sep 3, 2014, CVS Caremark Corporation announced a change of its corporate name to CVS Health to reflect its broader health care commitment. In Nov 2018, CVS Health completed the $70-billion consolidation of insurance-giant Aetna. With the acquisition, the segments of CVS Health have been realigned.
Zacks.com featured highlights StoneCo, CVS Health, KT, KB Financial and USANA Health Sciences
by Zacks Equity Research
STNE, CVS, KT, KB, and USNA stand out as low P/B stocks with strong EPS growth prospects for August portfolios.
5 Low Price-to-Book Stocks to Add to Your Portfolio in August
by Kinjel Shah
STNE, CVS, KT, KB and USNA stand out in August for low P/B ratios and strong growth forecasts, making them value stock contenders.
Here is What to Know Beyond Why CVS Health Corporation (CVS) is a Trending Stock
by Zacks Equity Research
CVS Health (CVS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
CVS Lifts 2025 Adjusted EPS Forecast Again: What's Driving the Move?
by Moumi Mondal
CVS Health boosts 2025 EPS guidance again as Health Care Benefits and PBM businesses drive growth.
4 Value Stocks to Shield Amid Labor Market and Trade Worries
by Sumit Singh
CVS, ITGR, ASB and FNB emerge as value picks amid trade tensions and labor market concerns, thanks to strong cash flow metrics.
Is It Worth Investing in CVS Health (CVS) Based on Wall Street's Bullish Views?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in CVS Health (CVS). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Zacks Investment Ideas feature highlights: CVS Health, Johnson & Johnson and Tenet Healthcare
by Zacks Equity Research
CVS, JNJ, and Tenet Healthcare shine as defensive picks with strong earnings momentum and attractive valuations.
3 Medical Stocks to Consider as Markets Take a Breather
by Shaun Pruitt
These top medical stocks may be able to provide defensive safety after President Trump's tariff hikes and July's unfavorable jobs report led to a market selloff.
Economy Heating Up on PCE for June
by Mark Vickery
Pre-market and bond yield numbers appear to be in reaction to this morning's economic posts.
PCE Comes in Warmer Than Expected
by Zacks Equity Research
PCE Comes in Warmer Than Expected.
CVS Stock Up on Q2 Earnings & Revenue Beat, '25 EPS View Raised
by Zacks Equity Research
CVS Health beats on Q2 earnings and raises 2025 EPS outlook, lifting shares nearly 8% on strong segment growth and margin gains.
CVS Health (CVS) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for CVS Health (CVS) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
CVS Health (CVS) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
CVS Health (CVS) delivered earnings and revenue surprises of +23.13% and +5.54%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Is CVS Health (CVS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how CVS Health (CVS) and Agenus (AGEN) have performed compared to their sector so far this year.
CVS Health Care Delivery: Will the Growth Momentum Last in Q2?
by Moumi Mondal
CVS' Health Care Delivery unit posts strong growth from Signify and Oak Street, but rising medical costs pose a near-term risk.
Will Exome and Genome Growth Boost WGS' Q2 Earnings?
by Zacks Equity Research
GeneDx is likely to have experienced a Q2 lift, backed by strong Exome and genome test volumes, new indications and strategic tech moves.
CVS or UnitedHealth: Which Stock Is a Better Buy Ahead of Q2 Earnings?
by Urmimala Biswas
CVS shows resilience with stable insurance margins and capital discipline, while UNH faces cost headwinds and a sharp earnings cut.
BrightSpring Health Services, Inc. (BTSG) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
BrightSpring Health Services, Inc. (BTSG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why CVS Health (CVS) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
CVS Health (CVS) Stock Slides as Market Rises: Facts to Know Before You Trade
by Zacks Equity Research
In the most recent trading session, CVS Health (CVS) closed at $58.75, indicating a -5.01% shift from the previous trading day.
CVS or DHR: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CVS vs. DHR: Which Stock Is the Better Value Option?
Can Robust Invisalign Momentum Drive Align Technology's Q2 Earnings?
by Zacks Equity Research
ALGN is likely to have delivered robust Q2 2025 performance as Invisalign traction and iTero upgrades gained steam across global markets.
CVS Health (CVS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
CVS Health (CVS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
CVS Q2 Estimates Dip: Is the Stock Still a Buy Ahead of Q2 Earnings?
by Urmimala Biswas
Earnings estimates for CVS dip ahead of Q2 results, but turnaround efforts in Aetna and PBM strength may offset pressure.